Vaxxinova Company Profile

Background

Vaxxinova is a global animal health company specializing in disease prevention for production animals. Established in 2010 and headquartered in Nijmegen, the Netherlands, Vaxxinova operates in over 60 countries, offering a comprehensive range of vaccines and diagnostic services. The company is committed to enhancing animal health and food safety through innovative solutions.

Key Strategic Focus

Vaxxinova's strategic focus encompasses:

Core Objectives: Developing and providing veterinary biologics and customized services to improve food animal health.

Areas of Specialization: Vaccines and diagnostics for livestock, including poultry, cattle, swine, and fish.

Key Technologies Utilized: Proprietary Siderophore Receptor and Porin (SRP) technology for vaccine development.

Primary Markets Targeted: Global markets with a focus on regions such as the United States, Europe, and Sub-Saharan Africa.

Financials and Funding

Vaxxinova is a privately held company and does not publicly disclose detailed financial information. In 2022, the company announced plans for a $10 million to $20 million investment to expand its manufacturing capabilities in Willmar, Minnesota.

Pipeline Development

Vaxxinova's pipeline includes:

Key Pipeline Candidates: Vaccines targeting diseases such as Avian Metapneumovirus (aMPV) and Salmonella.

Stages of Development: The company has received USDA approval for the importation of live aMPV vaccines into the U.S. market.

Target Conditions: Avian Metapneumovirus, Salmonella, and other infectious diseases affecting livestock.

Anticipated Milestones: Distribution of live aMPV vaccines is expected to commence in early 2025, focusing initially on the turkey industry.

Technological Platform and Innovation

Vaxxinova distinguishes itself through:

Proprietary Technologies: SRP technology, which induces host immunity against bacterial infections by targeting siderophore receptors and porins.

Significant Scientific Methods: Advanced molecular diagnostics, including gene sequencing and DNA fingerprinting, to develop targeted vaccines.

Leadership Team

Vaxxinova's leadership team includes:

Victor van Solinge: CEO of Vaxxinova International, overseeing global operations.

Jay Halliday: CEO of Vaxxinova US, leading the U.S. subsidiary.

James Poole: Chief Financial Officer, responsible for financial strategy.

Vikram Verma: Chief Scientific Officer, guiding research and development initiatives.

Melissa DeGroot: Director of Sales and Marketing, managing commercial strategies.

Leadership Changes

In 2018, Vaxxinova acquired Epitopix, a U.S.-based company specializing in veterinary vaccines, expanding its presence in the North American market.

Strategic Collaborations and Partnerships

Vaxxinova has strengthened its market position through strategic acquisitions:

Deltamune (Pty) Ltd: Acquired in July 2025, Deltamune specializes in African livestock solutions, enhancing Vaxxinova's presence in Sub-Saharan Africa.

Laboratório Biovet: Acquired in February 2018, Biovet is a Brazilian company with a strong presence in the animal health industry, expanding Vaxxinova's footprint in Latin America.

Market Insights and Competitor Analysis

The global animal health market is experiencing growth due to increasing demand for animal protein and the need for disease prevention in livestock. Key trends include the adoption of innovative vaccine technologies and a focus on sustainable animal farming practices.

Vaxxinova faces competition from other animal health companies such as Zoetis and Merck Animal Health. These competitors offer a range of vaccines and diagnostics for livestock, with Zoetis being a significant player in the industry.